Spyre Therapeutics SYRE
NASDAQ SYRE
$89.93 +0.90 (+1.01%)
At close: Oct 1, 2026 · 4:00 PM EDT

Spyre Therapeutics (SYRE) Tax Provisions (2021 - 2025)

Updated

Spyre Therapeutics (SYRE) reported Tax Provisions of -$15,000 for FY2025, compared with $51,000 in FY2024.

Analysis

Spyre Therapeutics (SYRE) Tax Provisions (2021 - 2025) Analysis & Trends

Dating back to FY2021, Spyre Therapeutics' Tax Provisions record includes 5 years.

  • Five-year annual Tax Provisions spans a low of -$136,000 in FY2022 and a high of $141,000 in FY2021.
  • According to Business Quant data, Tax Provisions came in at $51,000 in FY2024, -$26,000 in FY2023, -$136,000 in FY2022 and $141,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Taxes (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.21 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 662.00 Mn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 654.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -1.01 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -291.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 393.00 Mn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 242.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -407.00 Mn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 292.00 Mn
10 Spyre Therapeutics 7.84 Bn 7.84 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 -15,000.00
Dec 31, 2024 1,000.00
Sep 30, 2024 18,000.00
Mar 31, 2024 32,000.00
Sep 30, 2023 3,000.00
Jun 30, 2023 7,000.00
Mar 31, 2023 -36,000.00
Dec 31, 2022 38,000.00
Sep 30, 2022 -209,000.00
Jun 30, 2022 9,000.00
Dec 31, 2021 23,000.00
Sep 30, 2021 26,000.00
Jun 30, 2021 92,000.00
API Access

Spyre Therapeutics Tax Provisions API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=tax-provisions&ticker=SYRE&period=max&api_key=YOUR_API_KEY